Back to News
Market Impact: 0.3
Odyseey's OD-001 Shows Clinical Activity In Ulcerative Colitis, Advanced To Next Trial Stage
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Odyssey Therapeutics reported additional Phase 2a data supporting clinical activity for OD-001, an oral ulcerative colitis treatment. The findings strengthen evidence for the drug's potential as the company prepares to advance it into larger mid-stage studies; the provided article excerpt includes no numerical trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ODTX0.55
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally